Christopher Costello
Family Medicine · Mesa, AZNPI 1477038610
Payments from drug & device makers
Across 482 payments — averaging $18.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Biohaven Pharmaceuticals, Inc.$1K
- GSK$728
- Pfizer$612
- Lilly USA, LLC$519
- AstraZeneca$487
- plus $4K from 36 others
What the payments were for
- Consulting fees$8009%
- Food & beverage$8,14391%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$800
- FARXIGA$327
- BREZTRI$327
- AIRSUPRA$327
How this compares
$8,950 in reported general payments places this provider in the 90th percentile of 2,099 family medicine providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 55 | $75,761 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 62 | $69,144 |
| EliquisApixaban | 34 | $54,520 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 52 | $32,093 |
| OzempicSemaglutide | 20 | $23,931 |
| MounjaroTirzepatide | 12 | $23,450 |
| TrulicityDulaglutide | 18 | $22,288 |
| XareltoRivaroxaban | 16 | $19,542 |
| GemtesaVibegron | 21 | $18,854 |
| FarxigaDapagliflozin Propanediol | 15 | $15,017 |
| MyrbetriqMirabegron | 13 | $12,424 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 15 | $12,310 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 14 | $10,860 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $6,107 |
| Atorvastatin Calcium | 304 | $3,617 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr | $433 | $88,07170 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $728 | $75,25173 claims |
| PfizerEliquis | $612 | $54,52034 claims |
| Lilly USA, LLCMounjaro, Trulicity | $519 | $45,73830 claims |
| Novo NordiskOzempic | $481 | $23,93120 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $118 | $18,85421 claims |
| AstraZenecaFarxiga | $487 | $15,01715 claims |
| Astellas Pharma US IncMyrbetriq | $90 | $12,42413 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $417 | $10,86014 claims |
| AbbVieSynthroid | $1,362 | $71811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,099 family medicine providers in Arizona.
Other family medicine in Mesa
- Terry O'ReillyMesa$35.8M
- Corey AndersonMesa$21.5M
- Gerald ShockeyMesa$12.3M
- Rachel GreatwoodMesa$1.5M
- Donna DesantisMesa$776K
- Yadwinder DhillonMesa$445K
- Benjamin ClarkMesa$441K
- Suzanne BentzMesa$174K
- William ReedyMesa$168K
- Allan SooMesa$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.